QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:BLTE

Belite Bio (BLTE) Stock Price, News & Analysis

$38.37
-1.56 (-3.91%)
(As of 04:21 PM ET)
Today's Range
$37.02
$39.98
50-Day Range
$37.81
$48.01
52-Week Range
$11.00
$48.60
Volume
34,602 shs
Average Volume
67,580 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.83

Belite Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
16.8% Upside
$44.83 Price Target
Short Interest
Healthy
0.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Belite Bio in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.63) to ($0.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.68 out of 5 stars

Medical Sector

862nd out of 938 stocks

Pharmaceutical Preparations Industry

389th out of 425 stocks

BLTE stock logo

About Belite Bio Stock (NASDAQ:BLTE)

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE Stock Price History

BLTE Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Belite Bio is Now Oversold (BLTE)
Belite Bio Stock (NASDAQ:BLTE) Insider Trades
Belite Bio to Participate in the BTIG Ophthalmology Day
See More Headlines
Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BLTE
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.83
High Stock Price Target
$60.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+18.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-31,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.28 per share

Miscellaneous

Free Float
25,275,000
Market Cap
$1.10 billion
Optionable
Not Optionable
Beta
-1.55
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

BLTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings
or view top-rated stocks.

What is Belite Bio's stock price target for 2024?

7 equities research analysts have issued 12 month price targets for Belite Bio's stock. Their BLTE share price targets range from $25.00 to $60.00. On average, they anticipate the company's stock price to reach $44.83 in the next year. This suggests a possible upside of 16.8% from the stock's current price.
View analysts price targets for BLTE
or view top-rated stocks among Wall Street analysts.

How have BLTE shares performed in 2024?

Belite Bio's stock was trading at $45.75 at the start of the year. Since then, BLTE stock has decreased by 16.1% and is now trading at $38.37.
View the best growth stocks for 2024 here
.

Are investors shorting Belite Bio?

Belite Bio saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 59,500 shares, an increase of 20.7% from the February 29th total of 49,300 shares. Based on an average daily trading volume, of 74,100 shares, the short-interest ratio is currently 0.8 days.
View Belite Bio's Short Interest
.

When is Belite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BLTE earnings forecast
.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc (NASDAQ:BLTE) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09.

When did Belite Bio IPO?

Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

Who are Belite Bio's major shareholders?

Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (0.13%), Cubist Systematic Strategies LLC (0.06%), Point72 Asset Management L.P. (0.03%), Jump Financial LLC (0.02%) and Virtus ETF Advisers LLC (0.01%).

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLTE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners